Maria V. Irazabal

Acute kidney injury in patients with inactive cytochrome P450 polymorphisms.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease.

Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.

Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.

Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.

Experimental therapies and ongoing clinical trials to slow down progression of ADPKD.

Supervised segmentation of polycystic kidneys: a new application for stereology data.

Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Novel therapeutic approaches to autosomal dominant polycystic kidney disease.

Identification of Biomarkers for PKD1 Using Urinary Exosomes.

Effects of hydration in rats and mice with polycystic kidney disease.

Histiocytic glomerulopathy associated with macrophage activation syndrome.

Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease.

Volume regression of native polycystic kidneys after renal transplantation.

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).